XML 58 R46.htm IDEA: XBRL DOCUMENT v3.8.0.1
Divestiture and Divestiture-Related Items (Details)
3 Months Ended 6 Months Ended
Jul. 29, 2017
USD ($)
site
Oct. 27, 2017
USD ($)
Oct. 28, 2016
USD ($)
Oct. 27, 2017
USD ($)
Oct. 28, 2016
USD ($)
Apr. 28, 2017
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Proceeds from sale of businesses       $ 6,058,000,000 $ 0  
Gain on sale of businesses   $ (697,000,000) $ 0 (697,000,000) 0  
Divestiture-related items   67,000,000 $ 0 114,000,000 $ 0  
Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency Business            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Proceeds from sale of businesses $ 6,100,000,000          
Gain on sale of businesses $ (697,000,000)          
Sale of businesses, number of dedicated manufacturing sites | site 17          
Sale of businesses, transitional agreement, manufacture and supply services, term 5 years          
Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency Business | Disposal Group, Held-for-sale, Not Discontinued Operations            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Inventories, net           $ 371,000,000
Property, plant, and equipment, net           689,000,000
Goodwill           2,910,000,000
Other intangible assets, net           2,320,000,000
Total assets held for sale           6,290,000,000
Other accrued expenses           34,000,000
Accrued compensation and retirement benefits           12,000,000
Deferred tax liabilities           707,000,000
Other liabilities           1,000,000
Total liabilities held for sale           $ 754,000,000
Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency Business | Disposal group, disposed of by sale, not discontinued operations            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Divestiture-related items   $ 67,000,000        
Accelerated and incremental stock compensation expense       $ 16,000,000    
Maximum | Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency Business            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Sale of businesses, transitional agreement, administrative services, term 12 months